Glenmark Pharmaceuticals Ltd reports Q2 FY27 revenue of ₹4,247 crore, with like-for-like growth of approximately 20%
- Reported revenue fell 29.8% year on year and rose 5.7% sequentially; the annual comparison reflects deferred North America out-licensing income recognized in the prior-year quarter.
- EBITDA margin was 20.3%; adjusted net profit was ₹485 crore.
- Like-for-like revenue growth was approximately 14% in India and 31% in North America.